Translation of an ad hoc release published in German pursuant to Article 17 of Regulation (EU) No 596/2014

on Sept. 18, 2018 / 10:35 CET/CEST

Kleinostheim, 18 September 2018 - The Management Board of curasan AG (ISIN DE0005494538) today received information that the approval for Ceracell® Ortho Foam has been granted by the U.S. Food & Drug Administration (FDA).

However, the claim 'bioactive', which has also been applied for has not yet been approved by the FDA. Further necessary studies in the U.S. market environment will have to be conducted in the near future for this addition. A timeframe for this has not yet been established.

Contact at curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900 - 51
ir@curasan.com

Attachments

  • Original document
  • Permalink

Disclaimer

curasan AG published this content on 25 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 October 2018 13:13:04 UTC